Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake.

Bausch & Lomb is one of the largest vision care companies ... With an upcoming launch of multifocal and toric lenses in the Infuse line (daily silicone hydrogels), we expect Bausch to win over ...

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.24 per share a year ago.